NCT06771674 2025-09-09Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaHookipa Biotech GmbHCompleted662 enrolled